- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| Mi | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| Mi | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.06. | Psyence Biomedical Ltd.: Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 | 245 | Newsfile | Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") - the world's... ► Artikel lesen | |
| 17.06. | Psyence BioMed regains Nasdaq compliance following reverse stock split | 1 | Seeking Alpha | ||
| 17.06. | Psyence Biomedical regains Nasdaq compliance after reverse split | 4 | Investing.com | ||
| 17.06. | Psyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements | 173 | Newsfile | New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq... ► Artikel lesen | |
| 11.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi | 2 | Investing.com | ||
| 27.05. | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | 275 | Newsfile | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen | |
| 20.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.05. | Psyence Biomedical to execute 1-for-7.97 reverse stock split | 5 | Seeking Alpha | ||
| 01.05. | Psyence Biomedical kündigt Aktienzusammenlegung an | 6 | Investing.com Deutsch | ||
| 01.05. | Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split | 253 | Newsfile | New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation... ► Artikel lesen | |
| 23.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.04. | Psyence BioMed gets Nasdaq notice for non-compliance | 1 | Seeking Alpha | ||
| 18.04. | Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 427 | Newsfile | New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April... ► Artikel lesen | |
| 15.04. | Psyence BioMed erhöht Beteiligung an PsyLabs mit 500.000 US-Dollar Investition | 2 | Investing.com Deutsch | ||
| 15.04. | Psyence BioMed boosts stake in PsyLabs with $500k investment | 2 | Investing.com | ||
| 15.04. | Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement | 254 | Newsfile | New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into... ► Artikel lesen |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,210 | -2,84 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 0,800 | 0,00 % | Silexion Therapeutics Corp: Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers | GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| MINK THERAPEUTICS | 7,350 | 0,00 % | MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress | Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1-resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK... ► Artikel lesen | |
| QIAGEN | 40,760 | -1,14 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| BIONTECH | 90,95 | +0,33 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| EVOTEC | 7,112 | -1,17 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,260 | -2,77 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,430 | +0,27 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| ONCO-INNOVATIONS | 1,350 | +8,00 % | EQS-Media: Onco-Innovations Ltd.: Erhebliche Aufwärtsperspektive für frühe Investoren? Neue Studie unterstützt die Anwendbarkeit der Ergebnisse klinischer Lungenkrebsstudien | EQS-Media / 21.06.2025 / 15:37 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass die Mitbegründer seiner hundertprozentigen... ► Artikel lesen | |
| SEPTERNA | 10,870 | 0,00 % | Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside | ||
| LEXEO THERAPEUTICS | 4,180 | 0,00 % | Lexeo to help launch spinout around RNA drugs for the heart | ||
| OLEMA PHARMACEUTICALS | 4,580 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,010 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.